Investing

RAD 202 receives approval to start Phase 1 therapeutic trial

December 20, 2024 Investing 1 Min Read

Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial

Download the PDF here.

This post appeared first on investingnews.com

Fill Out & Get More Relevant News

Your name
Your email

Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.
Popular
Categories
- Business (66)
- Economy (44)
- Investing (131)
- Politics (159)